"Sweet Tooth"-Oriented SN38 Prodrug Delivery Nanoplatform for Targeted Gastric Cancer Therapy.

Ning Ding,Shengjun Xu,Sheng Zheng,Qianwei Ye,Li Xu,Sunbin Ling,Shanshan Xie,Wenwen Chen,Zizhen Zhang,Meng Xue,Zhenghua Lin,Xiao Xu,Liangjing Wang
DOI: https://doi.org/10.1039/d0tb02787a
IF: 7.571
2021-01-01
Journal of Materials Chemistry B
Abstract:Most cancer cells employ overexpression of glucose transports (GLUTs) to satisfy glucose demand ("Sweet Tooth") for increased aerobic glycolysis rates. GLUT1, one of the most widely expressed GLUTs in numerous cancers, was identified as a prognosis-related biomarker of gastric cancer via tissue array analysis. Herein, a "Sweet Tooth"-oriented SN38 prodrug delivery nanoplatform (Glu-SNP) was developed for targeted gastric cancer therapy. For this purpose, a SN38-derived prodrug (PLA-SN38) was synthesized by tethering 7-ethyl-10-hydroxycamptothecin (SN38) to biocompatible polylactic acid (PLA) with the appropriate degree of polymerization (n = 44). The PLA-SN38 conjugate was further assembled with glycosylated amphiphilic lipid to obtain glucosamine-decorated nanoparticles (Glu-SNP). Glu-SNP exhibited potent antitumor efficiency both in vitro and in vivo through enhanced cancer cell-specific targeting associated with the overexpression of GLUT1, which provides a promising approach for gastric cancer therapy.
What problem does this paper attempt to address?